Preliminary Experience of Cetuximab in the Treatment of Advanced-Stage Biliary Tract Cancer
Background: Cetuximab has been proved to be effective alone or in combination with other chemotherapeutic agents in the treatment of various malignancies. The aim of this report was to describe our experience of using cetuximab with chemotherapeutics agents to treat advanced-stage biliary tract canc...
Gespeichert in:
| Veröffentlicht in: | Oncology research and treatment 2010-01, Vol.33 (1-2), p.45-47 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 47 |
|---|---|
| container_issue | 1-2 |
| container_start_page | 45 |
| container_title | Oncology research and treatment |
| container_volume | 33 |
| creator | Chang, Ping-Ying Cheng, Ming-Fang Lee, Herng-Sheng Hsieh, Chung-Bao Yao, Nai-Shun |
| description | Background: Cetuximab has been proved to be effective alone or in combination with other chemotherapeutic agents in the treatment of various malignancies. The aim of this report was to describe our experience of using cetuximab with chemotherapeutics agents to treat advanced-stage biliary tract cancer. Case Reports: We retrospectively analyzed the outcomes of 5 biliary tract cancer patients receiving cetuximab-containing therapy. Four of them had stage IV disease, and 1 patient had incomplete resection at the time of diagnosis. Epidermal growth factor receptor (EGFR) expression and K-ras status were assessed when a specimen was available. After cetuximab treatment, complete response was achieved in 1 patient, partial response in 3 patients, and stable disease in 1 patient. Three surgical specimens were available, and all revealed positive EGFR expression. Only 1 surgical specimen was adequate for K-ras mutation test, and the wild type was confirmed. Complete response was found in the patient who had wild type K-ras. The progression-free survival of these patients varied from 4 to 16 months. Conclusions: Cetuximab-containing therapy might be an effective treatment for advanced biliary tract cancer. |
| doi_str_mv | 10.1159/000264613 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1159_000264613</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20164661</sourcerecordid><originalsourceid>FETCH-LOGICAL-c305t-ed0b3c4a44f6e6613d8a27becab5e84e69e2da91c6c53cb781c6f5ed6ef0b8f3</originalsourceid><addsrcrecordid>eNpFkM9LwzAcxYMobswdvIvk6qGapE3aHmeZP2CgYG8eSpp8M6NtN9JMtv_elOo8fR98P-_xeAhdUnJLKc_vCCFMJILGJ2jKWC4izgQ7PeqUTNC87z8DRhnnWZqfowkjNFgEnaL3VweNbW0n3QEv91twFjoFeGNwAX63t62sse2w_wBcOpC-hc4P34X-lgHU0ZuXa8D3trFDROmk8rgYXu4CnRnZ9DD_vTNUPizL4ilavTw-F4tVpGLCfQSa1LFKZJIYAaFUrDPJ0hqUrDlkCYgcmJY5VULxWNVpFpThoAUYUmcmnqGbMVa5Td87MNXWhdruUFFSDRNVx4kCez2y213dgj6Sf4ME4GoEvqRbg_sHRv8Pv1Nqxw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Preliminary Experience of Cetuximab in the Treatment of Advanced-Stage Biliary Tract Cancer</title><source>MEDLINE</source><source>Karger Journals</source><creator>Chang, Ping-Ying ; Cheng, Ming-Fang ; Lee, Herng-Sheng ; Hsieh, Chung-Bao ; Yao, Nai-Shun</creator><creatorcontrib>Chang, Ping-Ying ; Cheng, Ming-Fang ; Lee, Herng-Sheng ; Hsieh, Chung-Bao ; Yao, Nai-Shun</creatorcontrib><description>Background: Cetuximab has been proved to be effective alone or in combination with other chemotherapeutic agents in the treatment of various malignancies. The aim of this report was to describe our experience of using cetuximab with chemotherapeutics agents to treat advanced-stage biliary tract cancer. Case Reports: We retrospectively analyzed the outcomes of 5 biliary tract cancer patients receiving cetuximab-containing therapy. Four of them had stage IV disease, and 1 patient had incomplete resection at the time of diagnosis. Epidermal growth factor receptor (EGFR) expression and K-ras status were assessed when a specimen was available. After cetuximab treatment, complete response was achieved in 1 patient, partial response in 3 patients, and stable disease in 1 patient. Three surgical specimens were available, and all revealed positive EGFR expression. Only 1 surgical specimen was adequate for K-ras mutation test, and the wild type was confirmed. Complete response was found in the patient who had wild type K-ras. The progression-free survival of these patients varied from 4 to 16 months. Conclusions: Cetuximab-containing therapy might be an effective treatment for advanced biliary tract cancer.</description><identifier>ISSN: 2296-5270</identifier><identifier>ISSN: 0378-584X</identifier><identifier>EISSN: 2296-5262</identifier><identifier>EISSN: 1423-0240</identifier><identifier>DOI: 10.1159/000264613</identifier><identifier>PMID: 20164661</identifier><language>eng</language><publisher>Basel, Switzerland</publisher><subject><![CDATA[Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bile Duct Neoplasms - drug therapy ; Bile Duct Neoplasms - mortality ; Bile Duct Neoplasms - pathology ; Bile Ducts, Intrahepatic ; Camptothecin - administration & dosage ; Camptothecin - adverse effects ; Camptothecin - analogs & derivatives ; Case Report · Kasuistik ; Cetuximab ; Cholangiocarcinoma - drug therapy ; Cholangiocarcinoma - mortality ; Cholangiocarcinoma - pathology ; Combined Modality Therapy ; Deoxycytidine - administration & dosage ; Deoxycytidine - adverse effects ; Deoxycytidine - analogs & derivatives ; Disease Progression ; Drug Administration Schedule ; Female ; Fluorouracil - administration & dosage ; Fluorouracil - adverse effects ; Gallbladder Neoplasms - drug therapy ; Gallbladder Neoplasms - mortality ; Gallbladder Neoplasms - pathology ; Humans ; Leucovorin - administration & dosage ; Leucovorin - adverse effects ; Male ; Middle Aged ; Neoplasm Staging ; Survival Rate]]></subject><ispartof>Oncology research and treatment, 2010-01, Vol.33 (1-2), p.45-47</ispartof><rights>2010 S. Karger AG, Basel</rights><rights>(c) 2010 S. Karger AG, Basel.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c305t-ed0b3c4a44f6e6613d8a27becab5e84e69e2da91c6c53cb781c6f5ed6ef0b8f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20164661$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chang, Ping-Ying</creatorcontrib><creatorcontrib>Cheng, Ming-Fang</creatorcontrib><creatorcontrib>Lee, Herng-Sheng</creatorcontrib><creatorcontrib>Hsieh, Chung-Bao</creatorcontrib><creatorcontrib>Yao, Nai-Shun</creatorcontrib><title>Preliminary Experience of Cetuximab in the Treatment of Advanced-Stage Biliary Tract Cancer</title><title>Oncology research and treatment</title><addtitle>Oncol Res Treat</addtitle><description>Background: Cetuximab has been proved to be effective alone or in combination with other chemotherapeutic agents in the treatment of various malignancies. The aim of this report was to describe our experience of using cetuximab with chemotherapeutics agents to treat advanced-stage biliary tract cancer. Case Reports: We retrospectively analyzed the outcomes of 5 biliary tract cancer patients receiving cetuximab-containing therapy. Four of them had stage IV disease, and 1 patient had incomplete resection at the time of diagnosis. Epidermal growth factor receptor (EGFR) expression and K-ras status were assessed when a specimen was available. After cetuximab treatment, complete response was achieved in 1 patient, partial response in 3 patients, and stable disease in 1 patient. Three surgical specimens were available, and all revealed positive EGFR expression. Only 1 surgical specimen was adequate for K-ras mutation test, and the wild type was confirmed. Complete response was found in the patient who had wild type K-ras. The progression-free survival of these patients varied from 4 to 16 months. Conclusions: Cetuximab-containing therapy might be an effective treatment for advanced biliary tract cancer.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bile Duct Neoplasms - drug therapy</subject><subject>Bile Duct Neoplasms - mortality</subject><subject>Bile Duct Neoplasms - pathology</subject><subject>Bile Ducts, Intrahepatic</subject><subject>Camptothecin - administration & dosage</subject><subject>Camptothecin - adverse effects</subject><subject>Camptothecin - analogs & derivatives</subject><subject>Case Report · Kasuistik</subject><subject>Cetuximab</subject><subject>Cholangiocarcinoma - drug therapy</subject><subject>Cholangiocarcinoma - mortality</subject><subject>Cholangiocarcinoma - pathology</subject><subject>Combined Modality Therapy</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - adverse effects</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Disease Progression</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - adverse effects</subject><subject>Gallbladder Neoplasms - drug therapy</subject><subject>Gallbladder Neoplasms - mortality</subject><subject>Gallbladder Neoplasms - pathology</subject><subject>Humans</subject><subject>Leucovorin - administration & dosage</subject><subject>Leucovorin - adverse effects</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Survival Rate</subject><issn>2296-5270</issn><issn>0378-584X</issn><issn>2296-5262</issn><issn>1423-0240</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkM9LwzAcxYMobswdvIvk6qGapE3aHmeZP2CgYG8eSpp8M6NtN9JMtv_elOo8fR98P-_xeAhdUnJLKc_vCCFMJILGJ2jKWC4izgQ7PeqUTNC87z8DRhnnWZqfowkjNFgEnaL3VweNbW0n3QEv91twFjoFeGNwAX63t62sse2w_wBcOpC-hc4P34X-lgHU0ZuXa8D3trFDROmk8rgYXu4CnRnZ9DD_vTNUPizL4ilavTw-F4tVpGLCfQSa1LFKZJIYAaFUrDPJ0hqUrDlkCYgcmJY5VULxWNVpFpThoAUYUmcmnqGbMVa5Td87MNXWhdruUFFSDRNVx4kCez2y213dgj6Sf4ME4GoEvqRbg_sHRv8Pv1Nqxw</recordid><startdate>20100101</startdate><enddate>20100101</enddate><creator>Chang, Ping-Ying</creator><creator>Cheng, Ming-Fang</creator><creator>Lee, Herng-Sheng</creator><creator>Hsieh, Chung-Bao</creator><creator>Yao, Nai-Shun</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20100101</creationdate><title>Preliminary Experience of Cetuximab in the Treatment of Advanced-Stage Biliary Tract Cancer</title><author>Chang, Ping-Ying ; Cheng, Ming-Fang ; Lee, Herng-Sheng ; Hsieh, Chung-Bao ; Yao, Nai-Shun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c305t-ed0b3c4a44f6e6613d8a27becab5e84e69e2da91c6c53cb781c6f5ed6ef0b8f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bile Duct Neoplasms - drug therapy</topic><topic>Bile Duct Neoplasms - mortality</topic><topic>Bile Duct Neoplasms - pathology</topic><topic>Bile Ducts, Intrahepatic</topic><topic>Camptothecin - administration & dosage</topic><topic>Camptothecin - adverse effects</topic><topic>Camptothecin - analogs & derivatives</topic><topic>Case Report · Kasuistik</topic><topic>Cetuximab</topic><topic>Cholangiocarcinoma - drug therapy</topic><topic>Cholangiocarcinoma - mortality</topic><topic>Cholangiocarcinoma - pathology</topic><topic>Combined Modality Therapy</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - adverse effects</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Disease Progression</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - adverse effects</topic><topic>Gallbladder Neoplasms - drug therapy</topic><topic>Gallbladder Neoplasms - mortality</topic><topic>Gallbladder Neoplasms - pathology</topic><topic>Humans</topic><topic>Leucovorin - administration & dosage</topic><topic>Leucovorin - adverse effects</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chang, Ping-Ying</creatorcontrib><creatorcontrib>Cheng, Ming-Fang</creatorcontrib><creatorcontrib>Lee, Herng-Sheng</creatorcontrib><creatorcontrib>Hsieh, Chung-Bao</creatorcontrib><creatorcontrib>Yao, Nai-Shun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Oncology research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chang, Ping-Ying</au><au>Cheng, Ming-Fang</au><au>Lee, Herng-Sheng</au><au>Hsieh, Chung-Bao</au><au>Yao, Nai-Shun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preliminary Experience of Cetuximab in the Treatment of Advanced-Stage Biliary Tract Cancer</atitle><jtitle>Oncology research and treatment</jtitle><addtitle>Oncol Res Treat</addtitle><date>2010-01-01</date><risdate>2010</risdate><volume>33</volume><issue>1-2</issue><spage>45</spage><epage>47</epage><pages>45-47</pages><issn>2296-5270</issn><issn>0378-584X</issn><eissn>2296-5262</eissn><eissn>1423-0240</eissn><abstract>Background: Cetuximab has been proved to be effective alone or in combination with other chemotherapeutic agents in the treatment of various malignancies. The aim of this report was to describe our experience of using cetuximab with chemotherapeutics agents to treat advanced-stage biliary tract cancer. Case Reports: We retrospectively analyzed the outcomes of 5 biliary tract cancer patients receiving cetuximab-containing therapy. Four of them had stage IV disease, and 1 patient had incomplete resection at the time of diagnosis. Epidermal growth factor receptor (EGFR) expression and K-ras status were assessed when a specimen was available. After cetuximab treatment, complete response was achieved in 1 patient, partial response in 3 patients, and stable disease in 1 patient. Three surgical specimens were available, and all revealed positive EGFR expression. Only 1 surgical specimen was adequate for K-ras mutation test, and the wild type was confirmed. Complete response was found in the patient who had wild type K-ras. The progression-free survival of these patients varied from 4 to 16 months. Conclusions: Cetuximab-containing therapy might be an effective treatment for advanced biliary tract cancer.</abstract><cop>Basel, Switzerland</cop><pmid>20164661</pmid><doi>10.1159/000264613</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2296-5270 |
| ispartof | Oncology research and treatment, 2010-01, Vol.33 (1-2), p.45-47 |
| issn | 2296-5270 0378-584X 2296-5262 1423-0240 |
| language | eng |
| recordid | cdi_crossref_primary_10_1159_000264613 |
| source | MEDLINE; Karger Journals |
| subjects | Adult Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bile Duct Neoplasms - drug therapy Bile Duct Neoplasms - mortality Bile Duct Neoplasms - pathology Bile Ducts, Intrahepatic Camptothecin - administration & dosage Camptothecin - adverse effects Camptothecin - analogs & derivatives Case Report · Kasuistik Cetuximab Cholangiocarcinoma - drug therapy Cholangiocarcinoma - mortality Cholangiocarcinoma - pathology Combined Modality Therapy Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Disease Progression Drug Administration Schedule Female Fluorouracil - administration & dosage Fluorouracil - adverse effects Gallbladder Neoplasms - drug therapy Gallbladder Neoplasms - mortality Gallbladder Neoplasms - pathology Humans Leucovorin - administration & dosage Leucovorin - adverse effects Male Middle Aged Neoplasm Staging Survival Rate |
| title | Preliminary Experience of Cetuximab in the Treatment of Advanced-Stage Biliary Tract Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T13%3A02%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preliminary%20Experience%20of%20Cetuximab%20in%20the%20Treatment%20of%20Advanced-Stage%20Biliary%20Tract%20Cancer&rft.jtitle=Oncology%20research%20and%20treatment&rft.au=Chang,%20Ping-Ying&rft.date=2010-01-01&rft.volume=33&rft.issue=1-2&rft.spage=45&rft.epage=47&rft.pages=45-47&rft.issn=2296-5270&rft.eissn=2296-5262&rft_id=info:doi/10.1159/000264613&rft_dat=%3Cpubmed_cross%3E20164661%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/20164661&rfr_iscdi=true |